Realizing the Benefits of Connected Health in Respiratory Drug Delivery RDD Europe 26.04.2017 Bill Welch, CTO Phillips-Medisize Kevin Deane, EVP Medicom Innovation Partner
Workshop Objective and Agenda “Opportunities and Challenges in Respiratory Connected Health Systems” Topic Facilitator Timing Introductions and Agenda Bill 5´ Presentation Bill, Kevin 20´ Break-Out Session Two groups 20´ Presentations Each group to present 15´ 2
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery” • Developing a value proposition and connected device strategy • Treating & Monitoring Chronic Respiratory Diseases • Making the transition from clinicals to real-world scale-up • Brainstorming session on Opportunities and challenges with Connected Health in Respiratory therapies 3
The healthcare industry faces significant challenges • Healthcare costs are rising globally at an unsustainable level, placing greater scrutiny on prescription medicine prices, even though these account for only about 10% of overall spend • This places an ever increasing pressure on drug costs, with payers exerting greater buying pressure to reduce prescription medicine spend and achieve greater affordability for patients and providers • For many years the discussion has been moving towards ‘payment by result’, reimbursement based on outcome models • This is changing the way that pharma approaches drug development, pricing and launch 4
At the same time dosage forms are evolving and connected devices proliferate The value of drugs delivered through …while connectivity is becoming ubiquitous devices has increased 10-fold in 10 years • Devices are the norm for new medicinal treatments for • More connected devices than people chronic diseases • By 2020 the average person will have as many 6 ‘things’ on-line • Increasingly complex, targeted and personalized drugs • The uptake rate of digital infrastructure is occurring at a rate 5 mean devices will be ever more critical to patient times faster than the adoption rate of electricity and telephones acceptance and drug performance 5
With all of these challenges, how do Pharmaceutical R&D groups respond? Adopt a Patient-centric approach : For many drugs entering the market, the method of drug delivery becomes the key connection point between the drug (and by extension, the pharma company) and the patient. Therefore, devices and associated technologies are central to patient value and the determination of outcome benefit. Outcomes Inputs Outputs Cost per launch Value per launch R&D effectiveness R&D efficiency More value for the patient and the system More affordable drugs via less costly R&D via innovative drugs with high-quality information Source: Nature Reviews Drug Discovery 9, 203-214 (March 2010) Broadly, R&D productivity is the combination of efficiency and effectiveness • Much of the R&D productivity effort is focused on • Whereas R&D effectiveness focuses on patients, with efficiency : drug delivery integral to the strategy: > Streamlining internal development costs > It defines the therapy specific value that can be delivered to the patient and to other stakeholders > Outsourcing non-core activities > It defines opportunities of how this value can be > Licensing in higher risk candidate drugs delivered > Adopting a ‘fast to fail’ approach > And, it defines how therapy information should flow securely transfer data to healthcare 6 providers and stakeholders
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery” • Developing a value proposition and connected device strategy • Treating & Monitoring Chronic Respiratory Diseases • Making the transition from clinicals to real-world scale-up • Brainstorming session on Opportunities and challenges with Connected Health in Respiratory therapies 7
Connected health for improved Patient-centered treatment setup and outcome 8
A Connected Health approach should cover the entire Patient Care Journey Selling the DRUG Delivering OUTCOME Pre-prescription/Sales Operational HCP training Adherence/motivation Disease awareness Direct treatment impact Sales rep. engagement Patient, Caregiver and HCP Information sharing interaction Pre-prescription Prescription Retention Improve Patient Care Journey 9
General structure of a fully Connected Respiratory Health Service Setup 10
Comparing to the well-known Fitbit approach… Supporting (seemless) patient monitoring Medication adherence tracking Social Auxiliary engagement data and and patient motivation information 11
Workshop Presentation „Realizing the Benefits of Connected Health in Respiratory Drug Delivery” • Developing a value proposition and connected device strategy • Treating & Monitoring Chronic Respiratory Diseases • Making the transition from clinicals to real-world scale-up • Brainstorming session on Opportunities and challenges with Connected Health in Respiratory therapies 12
Our approach starts with needs and opportunities, identifying ‘best fit’ technologies at the end Working areas of a drug delivery strategy: Research on market opportunities and unmet needs in relation to the therapy, the competitive situation Identify technological platforms that support the identified therapy Identify drivers for execution in respect to segmentation, launch and specific device drivers. development Split up in short and long term (LCM) options Take into account constraints and uncertainties that exist around the specific case – both internally and externally 13
Integrated Device Development – a logical outcome of Device Strategy The Phillips-Medisize Value Proposition : Integrated Product and Manufacturing Development leads to reduced time-to-market and lower launch risk 14
Summary • Leverage partners with proven connected health experience in both drug delivery devices and software § Choose a partner & platform technology that can support your longer-term vision and advancing market expectations • Require platform approach that can be tailored to your needs, yet is extensible across your business as your connected health strategy and areas of disease focus evolve • Address your drug delivery device needs and primary packaging components early – to get a competitive advantage in your therapies • Use both Device Strategy to address an outcome-based solution, and a Manufacturing Strategy to get to market at target quality, cost, time, and risk 15
We look forward to interact ! Bill Welch Email: Bill.Welch@phillipsmedisize.com Kevin Deane Email: KDP@medicomip.com Bjørn Knud Andersen Email: BUA@medicomip.com
Recommend
More recommend
